Virica Biotech Inc. (“Virica”), a leading developer of cell enhancers for scaling of viral vectors and cell and gene therapies, announces a significant expansion of bioprocessing services through a strategic partnership with Carleton University in a PRESS RELEASE. "This multi-year, multi-million-dollar research and infrastructure partnership will help drive innovation and talent development in the Ottawa [...]
Cell & gene therapy (C>) is complex, expensive and lacks standardization. How do you effectively evaluate and make informed decisions to identify a winning viral vector production strategy to improve the accessibility & affordability of C>? We are thrilled to announce our Fast Facts video with Cell & Gene Insights, where our expert Andrea Vervoort, [...]
Virica Biotech Inc. (“Virica”), a leading developer of cell enhancers for scaling of viral vectors, as well as cell and gene therapies, announced today the expansion of their sales team along with a full presentation calendar in a PRESS RELEASE. Azra Benson, a veteran stem cell scientist with extensive commercial experience in the cell and [...]
Closing the gap: Modeling benefits of AAV scale-up using novel enhancers In partnership with Cell and Gene Insights, Virica will present on the benefits of viral sensitizers and show how bioprocessing modeling can be used to inform decisions related to scaling up or scaling out processes. Presenters will include; Dr. Jean-Simon Diallo (CEO Virica [...]
Innate cellular antiviral defences present a significant challenge to viral vector production and transduction for cell and gene therapy manufacturing. Learn about what they are, the challenges they pose and Virica's solution to mitigating its impact on viral vector yield and quality. View infographic here: Antiviral Defenses: What You Need to Know [...]
In this interview Jean-Simon Diallo, CEO and Scientific Founder, and JonDavid De Jong, VP Scientific Operations discuss the challenges antiviral defenses pose to the successful production of vaccines and advanced therapies and what Virica is doing to tackle this problem. Check out the interview with BioInsights here! Read full interview: Virica's BioInsights Interview
The impact of innate cellular antiviral defenses has emerged as a crucial area of investigation in viral vector manufacturing. Several recent publications have highlighted that the cell's natural response to the introduction of foreign genetic material can trigger defenses that hinder viral production efficiency. Although there have been any approaches to circumvent these barriers, the [...]
Virica is pleased to announce it is part of the Canadian Pandemic Preparedness Hub (CP2H), a new research hub designed to protect Canadians against future pandemics and emerging threats. This multidisciplinary hub is part of an investment by the Government of Canada to grow a strong and competitive biomanufacturing and life sciences sector. “To continue [...]
Dr. Jean-Simon Diallo, Virica’s Scientific Founder & CEO, attended and presented on the topic “Overcoming barriers in viral vector manufacturing: Small molecule targeting of antiviral defenses” at the recent Cell Culture Engineering conference. Key takeaways noted for Dr. Jean-Simon Diallo were: What was surprising: Several talks made mention of antiviral defenses as an impediment to manufacturing [...]
Ottawa, Canada – April 21, 2023 –Virica Biotech Inc. (“Virica”), a leading supplier and developer of novel viral enhancers, announced today it is expanding its bioprocessing facilities and increasing its capacity to scale up the manufacturing of viral medicines and vaccines. The Government of Ontario is supporting the expansion at sites in Ottawa with a [...]
